Primary Thrombosis Prophylaxis in Antiphospholipid (aPL) Antibody-Positive Patients: Where Do We Stand? The protective effect of low-dose aspirin against incident thrombosis in patients with clinically significant aPL profiles is not supported by randomized controlled data. The effectiveness of hydroxychloroquine, statins, or their combination remains to be determined by well-designed randomized controlled trials. Barbhaiya M. (PubMed) Curr Rheumatol Rep. 2010 Nov 23. (Also see: Antiphospholipid Syndrome)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
ISN Assistant News Guide
International Scleroderma Network(ISN)
Primary Thrombosis Prophylaxis in Antiphospholipid (aPL) Antibody-Positive Patients: Where Do We Stand?
No replies to this topic